Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2022 09:23 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022

HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with...
May 05, 2022 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ...
February 28, 2022 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

CSU Phase 1b multi-dose data expected in JulyCDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022Expanded...
February 22, 2022 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to...
February 10, 2022 16:05 ET | Source: Celldex Therapeutics, Inc.

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB...
December 08, 2021 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of...
November 12, 2021 07:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual...
November 11, 2021 07:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Participate in Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor...
November 09, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate...
September 29, 2021 00:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021

- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 -- Greatly improved patient quality of life and reduced disease impact -- Data further support 95% complete...